Year archive

Can-Fite BioPharma Ltd. — 2021 filings

All 151 regulatory filings released by Can-Fite BioPharma Ltd. (CANF) in 2021, sourced directly from the official regulator.

151 Filings

2021 Period

2021 filings (151)

Filing	Released	Lang
Regulatory Filings 2021 Regulatory Filings	2021-12-30	English
FORM D regarding ptivate placement Regulatory Filings	2021-12-30	English
FORM D regarding ptivate placement Regulatory Filings	2021-12-30	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-12-29	English
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Advanced Solid Tumors Regulatory Filings	2021-12-29	English
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Advanced Solid Tumors Report Publication Announcement	2021-12-29	English
6-K Warrants exercise documents Capital/Financing Update	2021-12-23	English
6-K Warrants exercise documents Report Publication Announcement	2021-12-23	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-12-23	English
Agreement by an institutional investor to exercise certain warrants to purchase up to an aggregate of 150,000,000 ordinary shares represented by 5,000,000 American Depositary Shares. Regulatory Filings	2021-12-20	English
Agreement by an institutional investor to exercise certain warrants to purchase up to an aggregate of 150,000,000 ordinary shares represented by 5,000,000 American Depositary Shares. Report Publication Announcement	2021-12-20	English
CURRENT REPORT Foreign Filer Report	2021-12-20	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-12-20	English
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study Regulatory Filings	2021-12-20	English
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study Report Publication Announcement	2021-12-20	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-12-07	English
Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022 Regulatory Filings	2021-12-07	English
Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022 Report Publication Announcement	2021-12-07	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-11-26	English
Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update Interim / Quarterly Report 9M 2021	2021-11-26	English
Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update Report Publication Announcement Q3 2021	2021-11-26	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-11-23	English
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis Regulatory Filings	2021-11-23	English
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis Report Publication Announcement	2021-11-23	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-10-28	English
Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico Regulatory Filings	2021-10-28	English
Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico Report Publication Announcement	2021-10-28	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-10-21	English
Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal Regulatory Filings	2021-10-21	English
Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal Report Publication Announcement	2021-10-21	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-09-02	English
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study Regulatory Filings	2021-09-02	English
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study Report Publication Announcement	2021-09-02	English
Regulatory Filings 2021 Regulatory Filings	2021-09-02	English
PROSPECTUS Prospectus	2021-09-01	English
424B3-prospectus 160,500,000 Ordinary Shares represented by5,350,000 American Depositary Shares Proxy Solicitation & Information Statement	2021-09-01	English
424B3-prospectus 160,500,000 Ordinary Shares represented by5,350,000 American Depositary Shares Report Publication Announcement	2021-09-01	English
Regulatory Filings 2021 Regulatory Filings	2021-09-01	English
Regulatory Filings 2021 Regulatory Filings	2021-09-01	English
Regulatory Filings 2021 Regulatory Filings	2021-09-01	English
FORM D-Notice of Exempt Offering of Securities Capital/Financing Update	2021-08-26	English
FORM D-Notice of Exempt Offering of Securities Regulatory Filings	2021-08-26	English
FORM F-1 REGISTRATION STATEMENT Capital/Financing Update	2021-08-26	English
FORM F-1 REGISTRATION STATEMENT Regulatory Filings	2021-08-26	English
REGISTRATION STATEMENT Regulatory Filings	2021-08-26	English
POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1 Regulatory Filings	2021-08-26	English
Regulatory Filings 2021 Regulatory Filings	2021-08-26	English
POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1 Capital/Financing Update	2021-08-26	English
POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1 Regulatory Filings	2021-08-26	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-08-26	English
results for the six months ended June 30, 2021 and updates on its drug development Interim / Quarterly Report H1 2021	2021-08-26	English
results for the six months ended June 30, 2021 and updates on its drug development Report Publication Announcement H1 2021	2021-08-26	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-08-16	English
US offering documents Regulatory Filings	2021-08-16	English
US offering documents Report Publication Announcement FY 2021	2021-08-16	English
PROSPECTUS SUPPLEMENT (To Prospectus dated October 9, 2020) Capital/Financing Update	2021-08-13	English
PROSPECTUS SUPPLEMENT (To Prospectus dated October 9, 2020) Report Publication Announcement	2021-08-13	English
PROSPECTUS SUPPLEMENT Prospectus	2021-08-13	English
CURRENT REPORT Foreign Filer Report	2021-08-12	English
Announces $10.0 Million Registered Direct Offering Regulatory Filings	2021-08-12	English
Announces $10.0 Million Registered Direct Offering Report Publication Announcement	2021-08-12	English
CURRENT REPORT OF PRIVATE ISSUER Foreign Filer Report	2021-08-05	English
Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board Regulatory Filings	2021-08-05	English
Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board Report Publication Announcement	2021-08-05	English
The Company’s Special Meeting was adjourned for one week and will be reconvened on August 5, 2021 Regulatory Filings	2021-07-29	English
The Company’s Special Meeting was adjourned for one week and will be reconvened on August 5, 2021 AGM Information	2021-07-29	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-07-29	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-07-08	English
Gears Up to Initiate Pivotal Phase III Liver Cancer Study Regulatory Filings	2021-07-08	English
Gears Up to Initiate Pivotal Phase III Liver Cancer Study Report Publication Announcement	2021-07-08	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-06-28	English
Can-Fite enters projected veterinary osteoarthritis market: Signs agreement with Vetbiolix for development of piclidenoson for pets Regulatory Filings	2021-06-28	English
Can-Fite enters projected veterinary osteoarthritis market: Signs agreement with Vetbiolix for development of piclidenoson for pets Report Publication Announcement	2021-06-28	English
6K:NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON July 29, 2021 Governance Information	2021-06-23	English
6K:NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON July 29, 2021 Proxy Solicitation & Information Statement	2021-06-23	English
6K:NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON July 29, 2021 Proxy Solicitation & Information Statement	2021-06-23	English
CURRENT REPORT Foreign Filer Report	2021-06-23	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-06-16	English
Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment Regulatory Filings	2021-06-16	English
Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment Report Publication Announcement	2021-06-16	English
Death of Israel Shamay, an external director of the Company Regulatory Filings	2021-06-14	English
Death of Israel Shamay, an external director of the Company Board/Management Information	2021-06-14	English
FORM 6-K Foreign Filer Report	2021-06-14	English
FORM 6-K-Israel Shamay, an external director of Can-Fite , passed away Regulatory Filings	2021-06-14	English
FORM 6-K-Israel Shamay, an external director of Can-Fite , passed away Board/Management Information	2021-06-14	English
Results of annual meeting held on June 7 2021 Regulatory Filings	2021-06-07	English
Results of annual meeting held on June 7 2021 AGM Information	2021-06-07	English
FORM 6-K Foreign Filer Report	2021-06-07	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-06-02	English
Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson Regulatory Filings	2021-06-02	English
Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson Report Publication Announcement	2021-06-02	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-06-01	English
The annual general meeting of shareholders which was scheduled for May 31, 2021 was postpned and will be reconvened on June 7, 2021 AGM Information	2021-06-01	English
The annual general meeting of shareholders which was scheduled for May 31, 2021 was postpned and will be reconvened on June 7, 2021 AGM Information	2021-06-01	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-05-27	English
First Quarter 2021 Financial Results & Provides Clinical Update Interim / Quarterly Report Q1 2021	2021-05-27	English
First Quarter 2021 Financial Results & Provides Clinical Update Report Publication Announcement	2021-05-27	English
CURRENT REPORT Foreign Filer Report	2021-04-29	English
Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 Regulatory Filings	2021-04-29	English
Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 Regulatory Filings	2021-04-29	English
Immediate Report of Meeting to be held on May 31,2021,proxy statement Board/Management Information	2021-04-23	English
Immediate Report of Meeting to be held on May 31,2021,proxy statement Proxy Solicitation & Information Statement	2021-04-23	English
Immediate Report of Meeting to be held on May 31,2021,proxy statement AGM Information	2021-04-23	English
Immediate Report of Meeting to be held on May 31,2021,proxy statement AGM Information	2021-04-23	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-04-23	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-04-22	English
Can-Fite Expands its Phase II COVID-19 Study to Europe Regulatory Filings	2021-04-22	English
Can-Fite Expands its Phase II COVID-19 Study to Europe Regulatory Filings	2021-04-22	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-04-20	English
Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates Regulatory Filings	2021-04-20	English
Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates Report Publication Announcement	2021-04-20	English
Regulatory Filings 2021 Regulatory Filings	2021-04-09	English
POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-1 Regulatory Filings	2021-04-05	English
POST-EFFECTIVE AMENDMENT TO FORM F-1 Capital/Financing Update	2021-04-05	English
POST-EFFECTIVE AMENDMENT TO FORM F-1 Regulatory Filings	2021-04-05	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-04-05	English
Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies Regulatory Filings	2021-04-05	English
Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies Report Publication Announcement	2021-04-05	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-03-30	English
Summary of existing out-licensing deals with potential milestone payments of up to approximately $130 million. In addition, to date~$20 million in non-dilutive upfront payment received Regulatory Filings	2021-03-30	English
Summary of existing out-licensing deals with potential milestone payments of up to approximately $130 million. In addition, to date~$20 million in non-dilutive upfront payment received Regulatory Filings	2021-03-30	English
CURRENT REPORT Foreign Filer Report	2021-03-25	English
ANNUAL REPORT Annual Report FY 2020	2021-03-25	English
Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update Earnings Release FY 2020	2021-03-25	English
Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update Report Publication Announcement	2021-03-25	English
FORM 20-F FOR 2020 Annual Report FY 2020	2021-03-25	English
FORM 20-F FOR 2020 Report Publication Announcement FY 2020	2021-03-25	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-03-18	English
Topical administration of CF602 fully recovers erectile dysfunction in diabetic model Regulatory Filings	2021-03-18	English
Topical administration of CF602 fully recovers erectile dysfunction in diabetic model Report Publication Announcement	2021-03-18	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-03-16	English
Can-Fite signs $42.7 million out-licensing deal with Ewopharma Regulatory Filings	2021-03-16	English
Can-Fite signs $42.7 million out-licensing deal with Ewopharma Report Publication Announcement	2021-03-16	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-03-05	English
Can-Fite enrolls first patient in Phase II COVID-19 study under FDA protocol Regulatory Filings	2021-03-05	English
Can-Fite enrolls first patient in Phase II COVID-19 study under FDA protocol Report Publication Announcement	2021-03-05	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-02-22	English
New positive data from Can-Fite’s liver cancer phase II clinical study with Namodenoson Regulatory Filings	2021-02-22	English
New positive data from Can-Fite’s liver cancer phase II clinical study with Namodenoson Report Publication Announcement	2021-02-22	English
SC 13G/A Major Shareholding Notification	2021-02-16	English
CANF 13GA Major Shareholding Notification	2021-02-09	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-02-01	English
Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies Regulatory Filings	2021-02-01	English
Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies Report Publication Announcement	2021-02-01	English
AMENDMENT NO. 2 TO SCHEDULE 13G Major Shareholding Notification	2021-01-29	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-01-28	English
Can-Fite’s NASH Indication Highlighted in Webinar by KOL Dr. Harrison: “Namodenoson May Have Big Impact on NASH” Regulatory Filings	2021-01-28	English
Can-Fite’s NASH Indication Highlighted in Webinar by KOL Dr. Harrison: “Namodenoson May Have Big Impact on NASH” Report Publication Announcement	2021-01-28	English
Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers” Regulatory Filings	2021-01-08	English
Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers” Regulatory Filings	2021-01-08	English
REPORT OF FOREIGN PRIVATE ISSUER Foreign Filer Report	2021-01-08	English

Filings by year

2026 69 filings
2025 144 filings
2024 140 filings
2023 170 filings
2022 110 filings
2021 151 filings
2020 315 filings
2019 251 filings
2018 150 filings
2017 166 filings
2016 178 filings
2015 160 filings
2014 129 filings
2013 34 filings
2012 2 filings